{"DataElement":{"publicId":"6010528","version":"1","preferredName":"Neuroblastoma Immunotherapy Administered Regimen Type","preferredDefinition":"Text term that represents the kind of immunotherapy regimen administered to treat neuroblastoma.","longName":"6010286v1.0:2018539v1.1","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6010286","version":"1","preferredName":"Neuroblastoma Immunotherapy Administered","preferredDefinition":"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation._Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect._The act of having given something (e.g., a medication or test).","longName":"6010284v1.0:2233610v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"6010284","version":"1","preferredName":"Neuroblastoma Immunotherapy","preferredDefinition":"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.:Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.","longName":"C3270:C15262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C50ABD4-9F49-2B61-E053-F662850A17C9","latestVersionIndicator":"Yes","beginDate":"2017-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-24","modifiedBy":"ONEDATA","dateModified":"2017-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C50ABD4-9F57-2B61-E053-F662850A17C9","latestVersionIndicator":"Yes","beginDate":"2017-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-24","modifiedBy":"COOPERM","dateModified":"2017-10-25","changeDescription":"Created for 8.21.17 request. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018539","version":"1.1","preferredName":"Immunotherapy Type","preferredDefinition":"the type of immunotherapy.","longName":"ITX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"BCG","valueDescription":"BCG","ValueMeaning":{"publicId":"2558275","version":"1","preferredName":"BCG","longName":"2558275","preferredDefinition":"An attenuated strain of Mycobacterium bovis with non-specific immunoadjuvant and immunotherapeutic properties. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG (Bacillus Calmette-Guerin) likely activates a Th1 cytokine response that includes induction of interferon.  Vaccination with BCG may be immunoprotective against infection with Mycobacterium tuberculosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG","conceptCode":"C1328","definition":"An attenuated strain of Mycobacterium bovis with non-specific immunoadjuvant and immunotherapeutic properties. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG (Bacillus Calmette-Guerin) likely activates a Th1 cytokine response that includes induction of interferon.  Vaccination with BCG may be immunoprotective against infection with Mycobacterium tuberculosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2017-10-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FAC-33FD-E053-F662850A9296","beginDate":"2002-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"Interferon","ValueMeaning":{"publicId":"2567432","version":"1","preferredName":"Interferon","longName":"2567432","preferredDefinition":"RAEB: Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. (MSH98)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D475-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FB6-33FD-E053-F662850A9296","beginDate":"2003-12-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FC0-33FD-E053-F662850A9296","beginDate":"2002-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"CTLA-4","valueDescription":"CTLA4 gene","ValueMeaning":{"publicId":"3270419","version":"1","preferredName":"CTLA4 gene","longName":"3270419","preferredDefinition":"This gene is involved in T-cell mediation and receptor signal transduction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CTLA4 Gene","conceptCode":"C28567","definition":"This gene is involved in T-cell mediation and receptor signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7043A2-385C-35BC-E040-BB89AD431942","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FCA-33FD-E053-F662850A9296","beginDate":"2017-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"PD1-based treatment","valueDescription":"PD1 Inhibitor Therapy","ValueMeaning":{"publicId":"5946188","version":"1","preferredName":"PD1 Inhibitor Therapy","longName":"5946188","preferredDefinition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PD1 Inhibitor","conceptCode":"C124946","definition":"An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57FD698F-5B7E-4236-E053-F662850AA0D2","latestVersionIndicator":"Yes","beginDate":"2017-08-30","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FD4-33FD-E053-F662850A9296","beginDate":"2017-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"Dinutuximab","valueDescription":"Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"3597790","version":"1","preferredName":"Monoclonal Antibody Ch14.18","longName":"3597790","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E763-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C60D3FF-3FDE-33FD-E053-F662850A9296","beginDate":"2017-10-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C60D3FF-3F95-33FD-E053-F662850A9296","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"COOPERM","dateModified":"2017-10-25","changeDescription":"Versioned to extend max length from 10 to 25. 10/25/17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5806867","version":"1","longName":"Neuroblastoma","context":"OCG"}]}],"AlternateNames":[{"name":"neuroblastoma_immunotherapy","type":"HCMI Name","context":"OCG"}],"ReferenceDocuments":[{"name":"Neuroblastoma immunotherapy t","type":"Preferred Question Text","description":"Neuroblastoma immunotherapy type","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C5D5BA5-6289-19FE-E053-F662850A6077","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-25","modifiedBy":"COOPERM","dateModified":"2017-10-25","changeDescription":"Created for request 8.21.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}